LOOK AT THIS STOCK, TAKE IT APART THEN DISSECT IT AGAIN A PUT IT THROUGH THE MIXER---IT WILL COME UP TRUMPS---EVERY TIME!

Look at the profitabilty of the new company, the products the market and the quality of the board.

At these prices this share is cheap.

PLEASE PROVE ME WRONG!

MLR----IF you want a safe sound solid retirement?

Check it out and see for yourselves!

One of the most secure ways to make, and safeguard your money in the financial market place today.

Rampity ramp, get a shed load guys, can't go wrong with this one, must phone me broker tomorrow, credit card at the ready ;)

Dave the Rave

What about BKE...you use to ramp that to death and then it died.

LOLOLOLOLOL

Can anybody understand the heading...he must be pissed again.

Oh dear...down again.

LOLOLOLOL

GENTLEMEN PLEASE YOU MUST LOOK LONG TERM WITH RECOVERY STOCKS. TWO YEARS FROM NOW MAELOR WILL BE A LEADING FORCE IN CRITCAL CARE.

JUST WATCH.

BUT IN INTEREST REALATED BLIPS LIKE THESE IT COULD FALL EVEN FURTHER, SURELY THATS THE NAME OF GAME, WHICH IS AFTER ALL A BIG BOYS GAME WHERE YOU TAKE THE UPS AND THE DOWNS IN YOUR STRIDE.

SHOULD IT FALL TO 12p, WATCH FOR A 200000 BUY, IT WILL BE MINE.

Have a really nice day

LOLOLOLOLOLOLOL...DREAMER.

7P HERE WE COME.

Would be much better for you to observe and avoid continually making a fool of yourself.

this is a solid good quality company..profit taking going on now but it'll be back up and more in the next few yrs....(imo)

Let the foolish ones ride alone skyhigh, its obvious that they are opportunists who cant see a proper deal if it hit them in the eye.

You have been doing that for years...it is clear you are fool by your heading...you can't even get that right..

A mis presented heading always gets attention, you really are quite limited in preception--why is that?

Would be much better for you to observe and avoid continually making a fool of yourself.

MLR is one of many companies in its field...a very small company in a very large world.

Very high risk.

Of course it is.

Arnt they all?

But dont we love the risk/reward?

If you want to score over the next two years, please study this company well.

Research the hell out of it and then you will see that buying into it is a sound investment.

Its a brand new company now and its only just starting to grow.

I cant say more than that.

Chatting around today chaps only to find a consensus between holders that there is no other reason for MLR to be marked down other than MMs sentiments.

Dont be fooled this is s great buying opportunity. as the company is A OK.

The SP will continue to decline until there is some positive news and this company has once again reported a loss...so IMHO the SP will decline rapidly.

BMW FORMALLY SQUELCHED SO YOU ARE TALKING TO YOURSELF AS USUAL.

Boo Hoo

Now, now , now baby BMW please dont be childish, some one will give your dummy back I am sure, meanwhile please dip deep into MLR you will make a mint in a very short time. FACT

I mean we are here to make money not trade insults.

Trading of insults you can do in any back street pub, but making money, real money takes education and class not crass.

You have just advised cynic to "come back in 2 years"...now you say I will make a mint in a short time.

The FACT is you do not appear to know the difference between FACT or FICTION.

come, come, come Sir in the magical world of stocks and shares two years is a very conservative short term, by the way, what world are you from?

furthermore you would be doing me a favour if you kept criticising MLR even though you have obviously not researched it-----and further by not, yes not buying it.

IN FACT BMW PLEASE DONT BUY IT!

Research...they are still making a loss, thats all the research I need to know.

Have a nice day.

Please Sir your ignorance is showing:-


Given the old saying that where ignorance is bliss etc I draw attention to the recent results below, I would also imagine that MLR have a lot of tax credits from all those unprofitable years - should help with the EPS.

I would estimate as a minimum that the Acorus acquisition should add at least 1m profitability to MLR. It would also seem that Maelor's organic growth should seem them produce at least a further 0.5m profitability in the next 12 months.

That gives an estinated PER of 11.5 based on current market cap of around 17.5m.

They will now prove to be a rapid growing company with I would have thought a PER of 15-20 being appropriate.

That possibly equates to potential share price growth over the next 12 months of 50-100% with a bit more if MLR are able to exceed expectations. Seems like good value to me with limited downside on a 12 month view, but please dont buy it stick to COH.

A BIT MORE FOR YOU---- CHEW ON IT WHILE CONSIDERING YOUR IGNORANCE!

Acorus audited results for year ended 30 September 2006

Acorus reported turnover of #3.04 million for the year ended 30 September 2006 (year ended 30 September 2005: #1.59 million).



Maelor PLC
05 June 2007


5th June 2007

Maelor plc

('Maelor', 'Group' or 'Company')


Maelor results ahead of expectations - profitable in H2


Preliminary Results for the year ended 31st March 2007


Maelor plc (AIM: MLR), the specialist hospital medicines company, announces
preliminary results for the year ended 31st March 2007.


Financial Highlights - Results ahead of expectations - profitable in H2

- Turnover up 53% to 2.84m (2006: 1.86m)
- Operating loss down to 73k (2006:609k / H1 93k)
- Earnings/loss per share reduced to 0.10p (2006:1.93p)
- Net cash position improved to 1.43m (2006:1.10m)

Operational Highlights - Transformational year

- Strong performance from underlying business

- Volplex sales tripled Vs 2005/06
- ISOplex and AquiHex into late stage development and on schedule
- Licence secured to supply 'specials'
- Initial payment received for Micelle Lidocaine
- 8% improvement in gross margin to 48% (2006: 40%)

- Further strengthened management team

- New Finance Director & Commercial Manager

- Transforming acquisition of Acorus Therapeutics Limited ('Acorus')
post year end

- Enlarged group profitable and growing
- Highly synergistic portfolio of products
- Integration progressing to schedule


Tim Wright, Chief Executive of Maelor plc said:


'This year has been transformational for Maelor. In line with our new strategy
developed in 2005/6 we have focused the Company on late stage and launched
products, managed the business to profitability in the second half of the year
and completed the acquisition of Acorus, thereby creating a substantial
specialist hospital medicine business which is profitable and cash generative.


Trading since the period end is in line with expectations and the integration of
Acorus is, as anticipated, proceeding smoothly. The enlarged business provides
us with a platform for further growth both organically and through further
acquisitions.'

- Ends -

For further information, call:
Tim Wright, Chief Executive T: +44(0) 1244 625150
Maelor plc

Matthew Hall/Sam Reynolds T: +44(0)20 7763 2200
Noble & Company Limited

Billy Clegg/Edward Westropp T: +44(0)20 7831 3113
Financial Dynamics


Chairman's Statement


Introduction


I am pleased to present the results for the past financial year, a year of
significant achievements for Maelor. Under the leadership of our CEO, Tim Wright
, the new management team has worked to transform the Company into a profitable
business with a focus on late stage specialist hospital medicines.


In my statement in the 2005-06 Annual Report I noted that for Maelor to
accelerate its growth we needed to succeed in marketing core products in our own
right and in partnering non-core products. In the year end March 2007 we
achieved both of these objectives with a threefold increase in sales of Volplex
and the exploitation of our micelle technology in a partnership with Plethora.
In addition we have further expanded our portfolio of critical care products
with the addition of AquiHexTM and ISOplexTM.


Our financial performance this year is much improved with the company reaching
breakeven in the second half of the year, resulting from an outstanding 53%
revenue growth. Our cash position has also strengthened and margins have been
substantially improved.



Acquisition


Since the year end, we have delivered a transforming, earnings enhancing
acquisition, which has made us profitable and built a strong platform for
growth. Acorus is a successful specialist pharmaceuticals and medical devices
company, which we acquired for a total consideration of 13 million. The initial
cash consideration was satisfied by the issue to institutional investors of
80,000,000 new Ordinary Shares of 10 pence each, which raised 8 million and was
oversubscribed.


Acorus is significantly profitable and growing with a portfolio of assets
primarily focused in critical care and neurology. It was established in 2000 and
has been built as a virtual company; thus the speed and success of our
integration process to date.


Outlook


Trading since the period end is in line with expectations and the integration of
Acorus is on schedule.


The existing business is now performing well. The acquisition of Acorus, with
its portfolio of marketed products will make us significantly profitable
creating a strong platform upon which to grow the business both organically and
through further acquisitions. The Board would like to thank the Maelor team for
its efforts and achievements during the year and it looks to the future with
confidence.


Chief Executive's Review


In my report last year we outlined our strategy to transform Maelor into a
specialist hospital medicine business, focused initially in critical care. We
identified the importance of focusing on late stage products, thereby reducing
the risk and expense of early stage development as well as leveraging our
non-critical care portfolio through efficient partnerships.


I am pleased to report that the implementation of this plan is progressing well
and has been significantly accelerated following the recently announced;
transforming acquisition of Acorus, creating a strong and profitable enlarged
Company.


Separating out the recent acquisition of Acorus, I am also pleased to report
that the underlying Maelor business has performed well over the year and in
particular has delivered a strong and profitable second half:

Building a specialist hospital medicines business


A significant contributor to this performance has been the successful
re-acquisition and re-launch of Volplex, a product Maelor originally developed
and licensed. Used in operating theatres and wards to maintain blood volume,
Volplex competes primarily with one other long established product.


We have succeeded in trebling sales of Volplex since March 2006 and MAT (moving
annual total) market share has grown from 12% to 20%. We have recruited an
experienced Commercial Manager and with substantial room for further market
share growth, the management team is confident that Maelor can continue to win
new customers and further grow sales of Volplex.


During the year we announced the late stage development of ISOplex and AquiHex,
both products which will be used in critical care settings. ISOplex, in common
with Volplex will be used in situations where an increase in blood volume is
required. ISOplex has been designed to mimic natural blood plasma, particularly
in the balance of electrolytes. The use of these 'isotonic' formulations is an
area of significant interest amongst critical care clinicians. Given our
experience and existing data in this sector it is anticipated that development
will be relatively rapid and inexpensive for a pharmaceutical product.
Development has continued to progress on schedule and regulatory approval
remains to be forecast for the end of 2008.


AquiHex is a 2% aqueous formulation of chlorhexidine, an antibacterial product
commonly used prior to surgical incision or insertion of IV lines. To date all
products of this type are alcohol based and therefore present problems in
settings where flammability is of concern such as operating theatres. Use of
alcohol based products is also recommended against when using certain IV lines
as it can make them brittle. AquiHex is being supplied as a 'special' ahead of
registration, which is currently forecast for late 2009.


In the middle of the year we succeeded in gaining approval to supply un-licensed
medicines. Generally known as 'specials' these products can be requested by
physicians for use in patients where there is a specific requirement which is
presently unmet by any medicine licensed in the UK. In addition to establishing
closer relationships with the critical care community this strategy will enable
Maelor to gauge demand for products and where this demand is sufficient,
progress these products to licence in the UK. We have recently gained
distribution rights to a selection of fluid and volume replacement products from
Germany which we also make available as part of this service.


Leverage non-critical care portfolio through efficient partnerships


We will continue to select strong partners to commercialise the heritage
portfolio of products and technologies that do not fit directly with the
Company's hospital specialist strategy, in particular our catheter flushing
solutions OptiFlo and Contisol and our proprietary early stage micelle
nanotechnology.


OptiFlo, the UK brand of catheter flushing solutions distributed by Bard,
continues to perform well, with sales up 6% versus 2005/2006, and remains the UK
market leader with a market share of 54%.


Included in the first half of the year is an initial payment following the
licensing of our proprietary micelle nanotechnology, micelle lidocaine. The
partnership with Plethora Solutions Holdings plc, a specialist urology company,
is progressing well and the product has successfully passed through the first
stage of its preclinical development programme. Under the terms of the
agreement Plethora is responsible for product development and distribution and
Maelor is entitled to milestone and royalty payments. The micelle lidocaine
technology will be incorporated into Plethora's on going product development
programme for the treatment of interstitial cystitis and painful bladder
syndrome. These distressing conditions are estimated to afflict up to two
million women in the United States and Europe.



Financial Summary


Financial results for the year ended 31 March 2007 have been delivered ahead of
expectations.


Turnover for the year to 31 March 2007 was 2.84m (2006: 1.86m), representing
an increase of 53% over prior year. This significant increase can be attributed
to the management team's continued focus on growing Volplex, the sales growth of
Optiflo as well as an initial payment received for our micelle lidocaine
nanotechnology.


Gross margins increased from last year by almost 8% to 48% as a result of
further efficiencies in manufacturing and supply.


The Group's operating loss for the year reduced significantly to 73k from 609k
in 2006, including achieving a 20k operating profit in the second half of the
year. The improvement was driven by the sales growth, the initial licensing
payment and careful cost control.


Group cash balances, net of debt, at 31 March 2007 were 1.43m compared with
1.10m last year. At the end of the year we sold our office building and
relocated to a modern leasehold property on Chester Business Park. Proceeds from
the sale of the building enabled the bank mortgage to be cleared leaving the
Company debt free at the year end. Since the year end we have negotiated a 2.0m
bank facility for further business expansion.



Acquisition of Acorus Therapeutics Limited


In line with the Company's strategy the most recent achievement was to
successfully complete a deal to acquire privately owned Acorus for a total
consideration of approximately 13.0m, comprising 7.0m in cash, 10 million
ordinary shares at 10p each and loan notes of 4.88m, contingent on achievement
of certain sales milestones.


The deal was funded by an oversubscribed placing of 80 million 10p ordinary
shares issued at 10p each and was completed on 10 May 2007. It is a transforming
move for Maelor, with the enlarged group becoming immediately profitable and
cash generative.


Acorus is a particularly synergistic acquisition. The product range is
complementary to Maelor's with the same customers, distribution channels and
regulatory systems and processes. The integration process is progressing well
and on schedule.


Outlook


Our vision remains to build a new force in specialist hospital medicine,
leveraging our expertise in both pharmaceuticals and medical devices. We have
re-focused the business, taken it to profitability in the second half and in
Acorus made a synergistic transformational acquisition. With a strong team in
place, Maelor is well-positioned to drive growth organically and through
acquisition.

This revenue generated gross profit of #2.13 million in 2006 (2005: #1.10 million) and made a profit after tax of #0.62 million (2005: profit of #0.04 million).

JUST A SMALL DETAIL OF AN "OPERATING LOSS", KEEPS ME FROM JUMPING IN...JUST A POSSIBILITY IT COULD GET WORSE....LOLOLOLOL

HAVE A NICE DAY.

Obviously you cant read, so stay ignorant and dont buy it!

Your loss.

Don't worry I won't...nobody in their right mind would buy either.

JUST GOES TO SHOW WHAT A CRETIN IN FULL FLIGHT LOOKS LIKE.

NO NEWS=NO RISE IN THE SP ONLY DOWN.

Please just dont buy it let others have a chance of profit.

MLR moved up today, Bid now 12p, this will be the start of the upward march--trust me, buy it at these crazy prices you just cant go wrong with this one..

Buying MLR today is batter than money in te bank chaps.

Do yourselves a favour and check it out it will fly soon mark my words.

Not a safer and surer buy in the market today.

In order to add a little confidence, I just added more to my portfolio because at these prices this is money for jam..these will fly soon and you will be kicking yourselves for not getting in whilst this stock is so cheap..

A 50000 sell reported on ADVFN TODAY WAS IN FACT A BUY, AS IT WAS MINE.

Have a really pleasant evening chaps.

having had a quick look at the chart, you had better hope there is good support at 12, for though you only put in another 5k, it smacks of trying to catch the proverbial falling knife

You may well be right, but it could go the other way too.

The problem at the moment is the issue price of 10p but long term its a good 'un..and my confidence is high.

Thanks for your input.

WELL CHAPS WHAT DOES ONE SAY?

My pet stock stuck in the doldrums and may well be chasing that 10p new issue price.

Let it drift there if it must but please keep a eye on it as it looks as if insituational buyers as watching the SP ready to jump in.

I am still plugging 20p short term (end of July), and I dont think that I will stupid enough to be giving AdieH and BMW the chance to come back at me.

The institutions are watching you...not MLR.

LOLOLOLOLOLOL

Now I like that one!!

The first sign of witt that you have shown, and truly indicative of a human life form.

Still might be interested if I can get it at or below the placing price - but reckon it could still continue to drift below that. Issue of wait and see.

Just on a point of interest what is your justification for saying that institutions are watching - do you have any tangible evidence of that - apart from the fact that they may have participated in the placing.

I cant really answer, that but if I were to the answer could well be an excited yes!

Please, for your pocket's welfare just keep watching.

What more can I say except have a great evening.

Why do you lie and say that institutions are watching.

Very misleading would'nt you say.

mg...what do you think.

misleading possibly but I never take advice from people who habitually shout on the bbs--it's intensely irritating and disrespectful!!

Hmmmmmmm - so there doesn't seem to be any substance in your over-enthusiastic statements. It seems you have invested heavily and you are trying to ramp up the stock. Many do it but I would be careful if I were you. Doesn't give you any credibility on what, on the whole, is a pretty sensible BB.

This isn't ADVFN - thank goodness !!

mmmmhhhn interesting!

I come form the old school of PR that claims---

"if you have something good to sell, no good shouting about it down a well".

AS I SAY THESE BBs ARE TO SHARE INFORMATION!

AND---- I ALSO INVITE EVERYONE TO DISSECT ANY SHARE I FEEL GOOD ABOUT AND SAY SO, AS I LIKE ANYONE CAN, AND DO, MAKE MISTAKES.

With that advice fully in mind it therefore becomes impossible to ramp any stock as each of us , as assumed responsible people, will have researched fully our buying decisions, or lack of them-

MLR has turned itself around for the better, its a new company now, and yes I have a very heavy investment in the company, which incidentanly is now "twice as heavy" since I originally bought in----therefore it is completely safe to say without a fear of being accused of ramping---- that it has been, to date, an extremely profitable venture.

And I honestly and most sincerely hold true that it will become an even more profitable investment, in facy hugely so!.

Look at this from ARMSHARE who rate MLR as a catergory "C" ----

C

These are companies, generally early-stage companies, almost none of which are making profits, but almost all of which are making sales: but all of which are showing some evidence of the form which could transform them into performing investments. END

Surely this is what the game is all about, we are all chasing the "big bucks" i.e to catch shares before they explode on the market and thereby only letting you in at a premium.

With my homework well and truly done on MLR there is only profit, a share price moving higher, and security attatched to an investment therein-

Now surely its an unwise move to level critism at me for wanting to share the information with you all.

Some of you may look at it and junk it others may act on it and buy it, but surely there will be an "individual's action" with no guns pointed at heads etc----We are therefore all BIG BOYS in a BIG BOYS game, are we not?

That being so it becomes impossible to ramp....and perhaps taking all the above into consideration, "suggest" emerges as a better choice of wording.

Lets all have a a nice civilised day here chaps.

David, take a look at your last few post regarding this one. It's pretty obvious that you believe there is money to be made here, but what you need to realise sometimes is your posting such a positive spin on this one.
Nothing wrong with that IMHO, it's your cash and only you stand to lose it if your wrong.

But take a step back and think of the abuse you have given aideh on the coh board about drawing in punters to lose money from constant rampings.

It does come around. I have no interest in this one at all and never will, but you can't have it both ways David.

I think you will find should you read back that the abuse initiated from AdieH.

I LIKE YOU, ONLY WANT IT ONE WAY, THAT BEING MONEY IN MY POCKET.

I DONT CRY SHOUT, YELL AND SCREAM WHEN SOMEONE DIGS AT MY SHARES--iN FACT TO BE HONEST I WELCOME IT AS I TOO MAKE MISTAKES.

AND BESIDES ITS A BIG BOYS GAME NO ROOM FOR CRY BABIES.

If you are such a big boy , why are you still balling your eyes out over BKE.

Oh come Sir enough of the childish subterfuge, show this BB my interest, past or presEnt in BKE.

YOU CANT-- AND YOU KNOW IT, AS ONLY A FOOL WOULD FOLLOW WORTHINGTON.

You really must stop blaming Worthington for your massive loss with BKE...surely the signs were there that BKE were in trouble, therefore you must take the blame for not jumping sooner to lessen your losses.

Simple really.

Come, come, come Sir, its plain to be seen that you have no substance and that you are talking through your very embarrassingly unpleasant lower anatomical orifice

Well Chaps I think we have found the bottom and the old worm has turned.

I dont wish to sound over presumptious but I feel that this share as it stands today is grossly undervalued by at least half and is a solid strong buy.

If you want to throw anything at me I promise to duck if its not five pound notes.

Once again you have stated that "ONLY A FOOL WOULD FOLLOW WORTHINGTON", for the benefit of the many posters on this BB can you explain as to why when I mentioned BKE you made the above statement.

BMW KINDLY GO THE THE APPROPRIATE BB AND LEVE THIS ONE FOR THE WINNERS.

Answer the question...we all know why you won't.

I have issued 2 warnings on seperate threads now - no more continuously going over the same points (it ruins the thread for all other posters) or I will remove access for all those involved.

Both sides have made their points - squelch each other.

Ian

I will conform Ian.

13.3% increase in the Sp today and moving up.


DONT FORGET TO RIP THIS COMPANY APART BEFORE YOU EVEN THINK OF BUY IN---YOU MUST BE SURE OF YOUR INVESTMENTS.

LOVELY END TO A GREAT DAY AND WITH 20/5p LOOMING IT CAN ONLY GET BETTER

10B ... so much phooey! ..... 13.3% of bugger all is still bugger all ...... though sp has poked its nose through 200 dma, it has yet to get near even 25 and 50 dma and all time high is 15.5p or thereabouts ..... i am afraid you sound awfully like maestro who regularly reckoned everyone should fill their boots with stocks x, y and z ..... fine if he had meant concrete!

Graet stuff I love to be criticised we should have more of it keep us on our toes.

To me 13.3% up is better that 13.3% down.

And you right it have yet to poke through up to 25 or even 50.

However if you did your homework the all time high was just under two pounds and it was a fraction of the compy then that it is today.

You sound a decent old boy and I hate to make you look silly, but I am affraid that I will have to in about six months time.

MLR will have motored by then.

Have a lovely evening and I look forward to perhaps some indepth reasoning from you on this company. Or should it be as you once stated too smaller a cap for you to bother?

I still say you should be filling your boots as you put it and if you do it will be with pound notes and not what seem to be bogging your thought down at the moment.

Lighten up lad its only a game.

come fly with me, come fly lets fly away!

Hark I hear a concrete mixer!